drugset / Trial / NCT01728298

A Dose Response Evaluation of SLITone Ultra HDM Mix Immunotherapy

NCT01728298 ↗

Phase 2 Completed 219 enrolled ALK-Abelló A/S
RandomizedParallel-groupOpen-labelTreatment

Summary

The primary objective of the trial is to evaluate the dose-response relationship with regards to change in immunological parameters and safety for SLITone ULTRA house dust mite mix in adult subjects with moderate to severe HDM allergic rhinitis.

Timeline

Start
2012-11
Primary completion
2013-08
Completion
2013-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator SLITone ULTRA HDM immunotherapy Unknown — —

Indications